
Insights
Why We Invested in Red Nucleus: A Pharma Commercialization Leader
Key Takeaways: In October 2024, THL announced its investment in Red Nucleus, a leading provider of pharma commercialization services. Pharma commercialization businesses are more critical than ever, as notable sector tailwinds — including the rise of complex therapies and a growing need for outsourced services — require specialized expertise to navigate market access, regulatory hurdles, and stakeholder
Healthcare (HC)